Inotec AMD
UK - CambridgeBiotechnology
Focus: Inotec AMD is a UK-based biotechnology company founded in 2023 specializing in oxygen wound therapy, with a focus on chronic and non-healing wound indications including diabetic foot ulcers and venous stasis ulcers.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Inotec AMD
AI assessmentNot HiringNo open roles listed right now. Follow Inotec AMD to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Natrox® Oxygen Wound Therapy
Diabetic Foot UlcerClinical Trials (1)
NCT03905863The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers
N/AHelp build intelligence for Inotec AMD
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.